{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:46:50Z","timestamp":1792799210268,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.critrevonc.2021.103339","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:28:26Z","timestamp":1618792106000},"page":"103339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-8355","authenticated-orcid":false,"given":"Kristian","family":"Egebjerg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra Singh","family":"Garbyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Preuss","family":"Hasselby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Baeksgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-1250","authenticated-orcid":false,"given":"Morten","family":"Mau-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103339_bib0005","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0360-3016(03)00782-X","article-title":"c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma","volume":"57","author":"Akamatsu","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0010","first-page":"4975","article-title":"Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma","volume":"33","author":"AM, K","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","article-title":"Global incidence of oesophageal cancer by histological subtype in 2012","volume":"64","author":"Arnold","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0020","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of american pathologists, american society for clinical pathology, and the american society of clinical oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0035","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1245\/s10434-011-1730-3","article-title":"Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression","volume":"18","author":"Birner","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cancergencyto.2005.08.031","article-title":"Alterations of the CCND1 and HER-2\/neu (ERBB2) proteins in esophageal and gastric cancers","volume":"165","author":"Bizari","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002742","article-title":"COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology","volume":"16","author":"Dekkers","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0050","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10517-010-1007-z","article-title":"Oncology: Squamous cell carcinoma of the esophagus: Evaluation of the status of epidermal growth factor receptors (EGFR and HER-2) by immunohistochemistry and in situ hybridization","volume":"149","author":"Delektorskaya","year":"2010","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1442-2050.2006.00570.x","article-title":"HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival","volume":"19","author":"Dreilich","year":"2006","journal-title":"Dis. Esophagus"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-14909-5","article-title":"Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance","volume":"7","author":"Du","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0065","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/ijc.28771","article-title":"EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer","volume":"135","author":"Fichter","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/13543784.2017.1315406","article-title":"Perspectives of HER2-targeting in gastric and esophageal cancer","volume":"26","author":"Gerson","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.bjc.6602625","article-title":"Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer","volume":"93","author":"Gibault","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0080","first-page":"25","article-title":"HER2 status in Barrett\u2019s esophagus & esophageal cancer: a meta analysis","volume":"5","author":"Gowryshankar","year":"2014","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0090","article-title":"Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer","volume":"2017","author":"Janmaat","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0095","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0100","article-title":"HER-2\/neu overxpression in esophageal squamous cell carcinoma (ESCC) and its correlation with patient\u2019s clinicopathological features","volume":"9","author":"Kermani","year":"2016","journal-title":"Int. J. Cancer Manag."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0105","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0110","first-page":"11","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"10","author":"Kurzrock","year":"2020","journal-title":"Oncol. Biomark. Dev."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ctrv.2008.09.003","article-title":"HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors","volume":"35","author":"Lisbet Nielsen","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0120","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/sj.bjc.6602499","article-title":"Frequencies of HER-2\/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma","volume":"92","author":"Mimura","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejso.2015.08.159","article-title":"HER2 expression in oesophageal carcinoma and Barrett\u2019s oesophagus associated adenocarcinoma: an Australian study","volume":"42","author":"Nagaraja","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/modpathol.3800712","article-title":"Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus","volume":"20","author":"Reichelt","year":"2007","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0135","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0140","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-9-6","article-title":"Evaluation of gene amplification and protein expression of HER-2\/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry","volume":"9","author":"Sato-Kuwabara","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0145","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/bjs.7562","article-title":"HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases","volume":"98","author":"Schoppmann","year":"2011","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0150","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1097\/PAS.0b013e3181f8be17","article-title":"Expression of her-2 in carcinomas of the esophagus","volume":"34","author":"Schoppmann","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0155","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1053\/j.gastro.2015.08.054","article-title":"Reviews in basic and clinical gastroenterology and hepatology recent advances from basic and clinical studies of esophageal squamous cell carcinoma","volume":"149","author":"Schwabe","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0160","first-page":"00866","article-title":"Treatment of locally advanced esophageal carcinoma: ASCO guideline","volume":"20","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol. JCO"},{"key":"10.1016\/j.critrevonc.2021.103339_bib0165","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1245\/s10434-012-2819-z","article-title":"KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review","volume":"20","author":"Shigaki","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0170","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00432-004-0610-7","article-title":"Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma","volume":"131","author":"Sunpaweravong","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0180","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional Cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0185","first-page":"493","article-title":"EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases","volume":"31","author":"Wei","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0190","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-180","article-title":"Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models","volume":"10","author":"Wu","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0195","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12032-011-9850-y","article-title":"Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma","volume":"29","author":"Zhan","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103339_bib0200","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0737-2","article-title":"Progress and challenges in HER2-positive gastroesophageal adenocarcinoma","volume":"12","author":"Zhao","year":"2019","journal-title":"J. Hematol. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282100127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282100127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:36:25Z","timestamp":1760902585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282100127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":40,"alternative-id":["S104084282100127X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103339","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103339"}}